February 08, 2010 (updated 11/16/2009)
This site was built to comply to Web authoring standards, and is best viewed in a standards-compliant browser. You may download one free from Netscape or Microsoft. You do not need to download a new browser, however, to have complete access to all information in this site.
Hollis-Eden Presents New Interim Data from Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics >>
Hollis-Eden to Present Interim Data from its Phase I/II Clinical Studies of Apoptone® (HE3235) at Molecular Targets and Cancer Therapeutics Conference – Company Provides Update on Progress of Lead Compounds – >>
Hollis-Eden Pharmaceuticals Retains Burrill LLC to Provide Exclusive Advisory Services for Lead Programs >>
Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price >>
Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO >>
 | 8-K Plan Rights Amendment |
 | Clinical Trials Update |
 | 2008 Annual Report and 2009 Proxy |
The Hollis-Eden Pharmaceuticals 2008 Annual Report and 2009 Proxy Notice, Statement and Card. >> | |
 | Clinical Trial Information |
Clinical Trial Information: Type 2 Diabetes, Ulcerative Colitis, Rheumatoid Arthritis, and Prostate Cancer. (click here) >> | |